Chemosaturation Percutaneous Hepatic Perfusion: A Systematic Review
详细信息 查看全文
- 作者：Arndt Vogel ; Sanjay Gupta ; Martin Zeile ; Rebecca von Haken…
- 关键词：Chemosaturation percutaneous hepatic perfusion ; Hepatic metastases ; Melphalan ; Oncology ; Primary liver tumors
- 刊名：Advances in Therapy
- 出版年：2017
- 出版时间：January 2017
- 年：2017
- 卷：33
- 期：12
- 页码：2122-2138
- 全文大小：747KB
- 刊物主题：Internal Medicine; Oncology; Cardiology; Rheumatology; Endocrinology; Pharmacology/Toxicology;
- 出版者：Springer Healthcare
- ISSN：1865-8652
- 卷排序：33
文摘
The Hepatic CHEMOSAT® Delivery System is an innovative medical device for the treatment of patients with unresectable primary liver tumors or unresectable hepatic metastases from solid organ malignancies. This system is used to perform chemosaturation percutaneous hepatic perfusion (CS-PHP), a procedure in which a high dose of the chemotherapeutic agent melphalan is delivered directly to the liver while limiting systemic exposure. In a clinical trial program, CS-PHP with melphalan significantly improved hepatic progression-free survival in patients with unresectable hepatic metastases from ocular or cutaneous melanoma. Clinically meaningful hepatic responses were also observed in patients with hepatocellular carcinoma or neuroendocrine tumors. Furthermore, the results of published studies and case reports demonstrated that CS-PHP with melphalan resulted in favorable tumor response rates in a range of tumor histologies (ocular or cutaneous melanoma, colorectal cancer, and hepatobiliary tumors). Analyses of the safety profile of CS-PHP revealed that the most common adverse effects were hematologic events (thrombocytopenia, anemia, and neutropenia), which were clinically manageable. Taken together, these findings indicate that CS-PHP is a promising locoregional therapy for patients with primary and secondary liver tumors and has a acceptable safety profile.